➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
McKesson
Medtronic
McKinsey

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

UKONIQ Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Ukoniq, and when can generic versions of Ukoniq launch?

Ukoniq is a drug marketed by Tg Theraps and is included in one NDA. There are seven patents protecting this drug.

This drug has sixty-six patent family members in thirty countries.

The generic ingredient in UKONIQ is umbralisib tosylate. Additional details are available on the umbralisib tosylate profile page.

DrugPatentWatch® Generic Entry Outlook for Ukoniq

Ukoniq will be eligible for patent challenges on February 5, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 26, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Get Started Free

Summary for UKONIQ
International Patents:66
US Patents:7
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 37
Patent Applications: 86
What excipients (inactive ingredients) are in UKONIQ?UKONIQ excipients list
DailyMed Link:UKONIQ at DailyMed
Drug patent expirations by year for UKONIQ
DrugPatentWatch® Estimated Generic Entry Opportunity Date for UKONIQ
Generic Entry Date for UKONIQ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for UKONIQ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 RX Yes Yes   Get Started Free   Get Started Free Y Y   Get Started Free
Tg Theraps UKONIQ umbralisib tosylate TABLET;ORAL 213176-001 Feb 5, 2021 RX Yes Yes   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Merck
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.